A NYT article has Wall Street abuzz today with whispers of non-profit hospital groups creating a new generics maker or partnering with third party manufacturers.
Guggenheim’s Rob Cihra is more confident than consensus on AAPL, calling for a strong performance in the fiscal year ahead.
Guggenheim’s Rohit Vanjani reacts to the debt rating downgrade on Teva from the sidelines without shock, having seen the writing on the wall.
One of Wall Street’s best analysts explains why the changes that have upset FB investors today will ultimately prove to be valuable longer-term.
Apple in strong standing for upside in its FQ1 print; Amazon showcases meaningful prospects to capture U.S. wallet share.